Etaluma

Executive Summary

Etaluma, Inc. is a U.S.-based medical device company specializing in compact, high-resolution inverted fluorescence microscopes for live-cell imaging. Founded in 2010 and headquartered in Carlsbad, California, the company's flagship Lumascope product line is designed for use inside incubators and environmental chambers, enabling long-term observation of biological processes. By offering affordable, user-friendly alternatives to traditional expensive microscopy systems, Etaluma targets academic research laboratories and biopharmaceutical companies seeking cost-effective solutions for cell biology and drug discovery. The company's focus on miniaturization and ease-of-use positions it as a disruptive player in the microscopy market, addressing the growing demand for accessible live-cell imaging tools. As a private company with no disclosed funding or revenue, Etaluma remains in an early growth phase. Its potential for expansion lies in leveraging its unique product differentiation to capture market share from established players like Nikon and Zeiss. Upcoming catalysts include the potential launch of a next-generation Lumascope model with enhanced imaging capabilities, strategic partnerships with biopharma firms for drug development workflows, and potential entry into clinical diagnostics with FDA clearance. While the company faces competition and scale-up challenges, its innovative approach and clear value proposition provide a solid foundation for growth.

Upcoming Catalysts (preview)

• TBDRelease of Next-Generation Lumascope with Improved Resolution and Automation60% success
• TBDStrategic Partnership with a Major Biopharma Company for Drug Discovery Applications50% success
• TBDFDA 510(k) Clearance for a Clinical Diagnostic Version of the Lumascope40% success